Severe Vasomotor Symptoms Post-Oophorectomy Despite Testosterone Therapy in a Transgender Man: A Unique Case Study
Open Access
- 13 February 2019
- journal article
- research article
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 3 (4) , 734-736
Abstract
Vasomotor symptoms (VMS) such as hot flashes and night sweats are intense and rapid sensations of internal heat, peripheral vasodilation, and profuse sweating that can be debilitating. They occur due to central norepinephrine discharge and narrowing of the core body thermoneutral zone with dropping brain estrogen levels in women and men. Therapy options for the treatment of VMS in post-menopausal women have been widely studied. However, the treatment strategies for VMS that occur in some transgender men who have undergone oophorectomy have not been reported. A 35-year-old female-to-male (FTM) transgender man presented with symptoms of severe and frequent VMS that began shortly after total hysterectomy and oophorectomy. The patient was treated with a stable dose of testosterone for gender affirmation and previous attempts to increase his testosterone dose did not relieve the VMS. In addition to his testosterone therapy, 0.025 - 0.0375 mg twice per week of transdermal estradiol was added to his hormonal regimen. Addition of estradiol completely relieved the vasomotor symptoms and masculinization was not affected. Discontinuation of estradiol led to the recurrence of VMS at the same severity as previously experienced, which was associated with a low level of serum estrogen. Vasomotor symptoms in a transgender man taking testosterone were successfully treated with the addition of transdermal estradiol.Keywords
Funding Information
- National Institutes of Health (T32DK007011)
This publication has 13 references indexed in Scilit:
- High Estrogen in Men After Injectable Testosterone TherapyAmerican Journal of Men's Health, 2014
- Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)The Lancet Oncology, 2013
- Oral micronized progesterone for vasomotor symptoms—a placebo-controlled randomized trial in healthy postmenopausal womenMenopause, 2012
- Progesterone for hot flush and night sweat treatment – effectiveness for severe vasomotor symptoms and lack of withdrawal reboundGynecological Endocrinology, 2012
- Estrogens in Men: Clinical Implications for Sexual Function and the Treatment of Testosterone DeficiencyThe Journal of Sexual Medicine, 2012
- Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trialThe Lancet Oncology, 2010
- Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushesCochrane Database of Systematic Reviews, 2004
- Hot flushes and prostate cancer: pathogenesis and treatmentBJU International, 2002
- Estrogen therapy and liver function—metabolic effects of oral and parenteral administrationThe Prostate, 1989
- Increased Estrogen Production in Obese Men*The Journal of Clinical Endocrinology & Metabolism, 1979